Abstract
The cancer-testis antigen NY-ESO-1 is a potential target antigen for immune therapy expressed in a subset of patients with multiple myeloma. We generated chimeric antigen receptors (CARs) recognizing the immunodominant NY-ESO-1 peptide 157–165 in the context of HLA-A*02:01 to re-direct autologous CD8+ T cells towards NY-ESO-1+ myeloma cells. These re-directed T cells specifically lysed NY-ESO-1157–165/HLA-A*02:01-positive cells and secreted IFNγ. A total of 40% of CCR7− re-directed T cells had an effector memory phenotype and 5% a central memory phenotype. Based on CCR7 cell sorting, effector and memory CAR-positive T cells were separated and CCR7+ memory cells demonstrated after antigen-specific re-stimulation downregulation of CCR7 as sign of differentiation towards effector cells accompanied by an increased secretion of memory signature cytokines such as IL-2. To evaluate NY-ESO-1 as potential target antigen, we screened 78 bone marrow biopsies of multiple myeloma patients where NY-ESO-1 protein was found to be expressed by immunohistochemistry in 9.7% of samples. Adoptively transferred NY-ESO-1-specific re-directed T cells protected mice against challenge with endogenously NY-ESO-1-positive myeloma cells in a xenograft model. In conclusion, re-directed effector- and central memory T cells specifically recognized NY-ESO-1157–165/ HLA-A*02:01-positive cells resulting in antigen-specific functionality in vitro and in vivo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046–1060.
Gay F, Palumbo A . Management of older patients with multiple myeloma. Blood Rev 2011; 25: 65–73.
Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521–2526.
Szmania S, Tricot G, van Rhee F . NY-ESO-1 immunotherapy for multiple myeloma. Leuk Lymphoma 2006; 47: 2037–2048.
Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B et al. Long-term follow up of a comparison of non-myeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011; 117: 6721–6727.
Kyle RA, Rajkumar SV . Multiple myeloma. N Engl J Med 2004; 351: 1860–1873.
Bleakley M, Riddell SR . Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004; 4: 371–380.
Hambach L, Goulmy E . Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 2005; 17: 202–210.
Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1–30.
Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265–270.
Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000; 97: 12198–12203.
van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005; 105: 3939–3944.
Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY et al. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur J Immunol 2004; 34: 2919–2929.
Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci USA 2009; 106: 5784–5788.
Kershaw MH, Teng MW, Smyth MJ, Darcy PK . Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005; 5: 928–940.
Porter DL, Levine BL, Kalos M, Bagg A, June CH . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725–733.
Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C et al. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res 2001; 61: 1976–1982.
Petrausch U, Haley D, Miller W, Floyd K, Urba WJ, Walker E . Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data. Cytometry A 2006; 69: 1162–1173.
June CH . Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117: 1466–1476.
Rosenberg SA, Dudley ME . Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21: 233–240.
Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL . T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005; 174: 7853–7858.
Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001; 167: 6123–6131.
Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 2003; 63: 2470–2476.
Sallusto F, Geginat J, Lanzavecchia A . Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745–763.
van Baarle D, Kostense S, van Oers MH, Hamann D, Miedema F . Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol 2002; 23: 586–591.
Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4: 225–234.
Ahmed R, Bevan MJ, Reiner SL, Fearon DT . The precursors of memory: models and controversies. Nat Rev Immunol 2009; 9: 662–668.
Klebanoff CA, Gattinoni L, Restifo NP . CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211: 214–224.
Kern F, Khatamzas E, Surel I, Frommel C, Reinke P, Waldrop SL et al. Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur J Immunol 1999; 29: 2908–2915.
Geginat J, Lanzavecchia A, Sallusto F . Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003; 101: 4260–4266.
Walker EB, Haley D, Petrausch U, Floyd K, Miller W, Sanjuan N et al. Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res 2008; 14: 5270–5283.
Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL . Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol 2008; 36: 1318–1328.
Neeson P, Shin A, Tainton KM, Guru P, Prince HM, Harrison SJ et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Therapy 2010; 17: 1105–1116.
Cui W, Kaech SM . Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev 2010; 236: 151–166.
Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A . Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708–712.
Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR . Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 2012; 119: 72–82.
Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007; 109: 1103–1112.
de Carvalho F, Vettore AL, Inaoka RJ, Karia B, Andrade VC, Gnjatic S et al. Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. Cancer Immun 2011; 11: 1.
Miyakawa Y, Ohnishi Y, Tomisawa M, Monnai M, Kohmura K, Ueyama Y et al. Establishment of a new model of human multiple myeloma using NOD/SCID/gamma(null)(c) (NOG) mice. Biochem Biophys Res Commun 2004; 313: 258–262.
Kirchgessner CU, Patil CK, Evans JW, Cuomo CA, Fried LM, Carter T et al. DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science 1995; 267: 1178–1183.
Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183: 5563–5574.
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
Weijtens ME, Willemsen RA, van Krimpen BA, Bolhuis RL . Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int J Cancer 1998; 77: 181–187.
Hombach A, Schneider C, Sent D, Koch D, Willemsen RA, Diehl V et al. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int J Cancer 2000; 88: 115–120.
Hombach A, Koch D, Sircar R, Heuser C, Diehl V, Kruis W et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Therapy 1999; 6: 300–304.
Tinguely M, Jenni B, Reineke T, Korol D, Kofler A, Rousson V et al. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays. Am J Surg Pathol 2007; 31: 690–696.
Acknowledgements
We would like to thank S Kleber, M Storz and M Glönkler for excellent technical assistance. Furthermore, we thank S Böttcher and R Müller (Department of Hematology, University Hospital Zurich, Switzerland) for support with flow cytometry. We thank P Romero (LICR, Lausanne, Switzerland) for the HLA-A*02:01-restricted NY-ESO-1157–165 (SLLMWITQC) peptide-specific, PE-conjugated tetramer. This study was funded by the ‘Dr Arnold U. und Susanne Huggenberger-Bischoff Stiftung zur Krebsforschung’ (UP); Cancer Research Institute; Ludwig Institute of Cancer Research; Krebsliga Zurich (all CR).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest
Additional information
Supplementary Information accompanies the paper on Gene Therapy website
Supplementary information
Rights and permissions
About this article
Cite this article
Schuberth, P., Jakka, G., Jensen, S. et al. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther 20, 386–395 (2013). https://doi.org/10.1038/gt.2012.48
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2012.48
Keywords
This article is cited by
-
CAR T therapies in multiple myeloma: unleashing the future
Cancer Gene Therapy (2024)
-
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
Stem Cell Research & Therapy (2021)
-
TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
Cancer Gene Therapy (2021)
-
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
Journal of Translational Medicine (2020)
-
Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
Cancer Immunology, Immunotherapy (2020)